LT2490532T - Naujos kompozicijos centrinės nervų sistemos degeneratyvinių sutrikimų profilaktikai ir (arba) gydymui - Google Patents

Naujos kompozicijos centrinės nervų sistemos degeneratyvinių sutrikimų profilaktikai ir (arba) gydymui

Info

Publication number: LT2490532T
Authority: LT; Lithuania
Prior art keywords: preventing; nervous system; central nervous; novel compositions; degenerative disorders
Prior art date: 2009-10-19

Application number

LTEP10825396.4T

Other languages

English (en)

Inventor

Robert Boyd

Gary Lee

Philip Rybczynski

Original Assignee

Amicus Therapeutics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-19

Filing date

2010-10-05

Publication date

2017-03-27

2010-10-05 Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.

2017-03-27 Publication of LT2490532T publication Critical patent/LT2490532T/lt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

LTEP10825396.4T 2009-10-19 2010-10-05 Naujos kompozicijos centrinės nervų sistemos degeneratyvinių sutrikimų profilaktikai ir (arba) gydymui LT2490532T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25280309P	2009-10-19	2009-10-19
PCT/US2010/051447 WO2011049736A1 (en)	2009-10-19	2010-10-05	Novel compositions for preventing and/or treating degenerative disorders of the central nervous system

Publications (1)

Publication Number	Publication Date
LT2490532T true LT2490532T (lt)	2017-03-27

Family

ID=43879775

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP10825396.4T LT2490532T (lt)	2009-10-19	2010-10-05	Naujos kompozicijos centrinės nervų sistemos degeneratyvinių sutrikimų profilaktikai ir (arba) gydymui

Country Status (27)

Country	Link
US (4)	US8604206B2 (lt)
EP (2)	EP3143875B1 (lt)
JP (2)	JP5805649B2 (lt)
KR (3)	KR101769396B1 (lt)
CN (2)	CN105367485B (lt)
AR (1)	AR078606A1 (lt)
AU (3)	AU2010308396B2 (lt)
BR (1)	BR112012009121A2 (lt)
CA (1)	CA2778348C (lt)
CY (1)	CY1118966T1 (lt)
DK (1)	DK2490532T3 (lt)
ES (2)	ES2814178T3 (lt)
HK (1)	HK1219724A1 (lt)
HR (1)	HRP20170236T1 (lt)
HU (1)	HUE033116T2 (lt)
IL (1)	IL219160B (lt)
LT (1)	LT2490532T (lt)
MX (2)	MX340807B (lt)
PL (1)	PL2490532T3 (lt)
PT (1)	PT2490532T (lt)
RS (1)	RS55679B1 (lt)
RU (2)	RU2581058C2 (lt)
SG (1)	SG10201507159XA (lt)
SI (1)	SI2490532T1 (lt)
SM (1)	SMT201700105B (lt)
TW (1)	TWI642434B (lt)
WO (1)	WO2011049736A1 (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2490532T3 (pl)	2009-10-19	2017-05-31	Amicus Therapeutics, Inc.	Nowe kompozycje do zapobiegania i/lub leczenia zaburzeń zwyrodnieniowych ośrodkowego układu nerwowego
ES2716871T3 (es)	2009-10-19	2019-06-17	Amicus Therapeutics Inc	Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal
EP2591823A1 (en) *	2011-11-11	2013-05-15	Biologische Heilmittel Heel GmbH	Composition for treating or preventing neurodegenerative disorders
CA2868459A1 (en)	2012-03-27	2013-10-03	Amicus Therapeutics, Inc.	Polymorphs of (3r,4r,5s)-5-(difluoromethyl)piperidine-3,4-diol fumarate and uses thereof
WO2015095963A1 (en) *	2013-12-23	2015-07-02	Alectos Therapeutics Inc.	Glucocerebrosidase modulators and uses thereof
US10179128B2 (en)	2015-08-31	2019-01-15	Amicus Therapeutics, Inc.	Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
US11358926B2 (en)	2017-04-25	2022-06-14	Amicus Therapeutics, Inc.	Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
RU2676956C1 (ru) *	2017-08-25	2019-01-11	Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум"	Антитела для связывания имиглюцеразы и их применение в аффинной хроматографии
KR101991276B1 (ko)	2018-01-19	2019-06-21	전남대학교산학협력단	신규 균주 페니실리움 아쿠아티쿰 및 이를 이용한 퇴행성 뇌질환 치료제
WO2020023390A1 (en)	2018-07-25	2020-01-30	Modernatx, Inc.	Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
US20240252418A1 (en) *	2023-01-31	2024-08-01	Bioeutectics Corporation	Additives (Adjuvants, Anti Freezing Agents, Antimicrobial and Antioxidants) in Natural Deep Eutectic Solvents and Mixtures

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4407957A (en)	1981-03-13	1983-10-04	Damon Corporation	Reversible microencapsulation of a core material
AU666118B2 (en)	1991-04-25	1996-02-01	Brown University Research Foundation	Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US5569189A (en)	1992-09-28	1996-10-29	Equidyne Systems, Inc.	hypodermic jet injector
DE69332105T2 (de)	1992-09-29	2003-03-06	Inhale Therapeutic Systems, San Carlos	Pulmonale abgabe von aktiven fragmenten des parathormons
DE69531098T2 (de)	1994-03-09	2004-04-29	Novo Nordisk A/S	Piperidine und pyrrolidine
US5863903A (en) *	1994-03-09	1999-01-26	Novo Nordisk A/S	Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2718357B1 (fr)	1994-04-06	1997-10-03	Defarges Alain Moreau	Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en)	1995-01-09	1997-02-04	Medi-Ject Corporation	Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en)	1995-04-14	1998-07-14	Inhale Therapeutic Systems	Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en)	1995-06-07	1997-08-05	Inhale Therapeutic Systems	Methods and system for processing dispersible fine powders
TW498067B (en) *	1996-07-19	2002-08-11	Hoffmann La Roche	4-hydroxy-piperidine derivatives
US6274597B1 (en) *	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
US20040082641A1 (en) *	2002-10-28	2004-04-29	Rytved Klaus Asger	Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
AU2003273762A1 (en) *	2002-10-28	2004-05-13	Novo Nordisk A/S	Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US7446098B2 (en)	2003-02-18	2008-11-04	Mount Sinai School Of Medicine Of New York University	Combination therapy for treating protein deficiencies
JP2007516294A (ja) *	2003-12-23	2007-06-21	エムユーエスシーファウンデーションフォーリサーチディベロップメント	炎症性の疾患または症状の予防および治療のための方法および組成物
ES2364586T3 (es) *	2006-05-24	2011-09-07	Amicus Therapeutics, Inc.	Sal tartrato de isofagomina y métodos de uso.
US7501439B2 (en) *	2006-05-24	2009-03-10	Amicus Therapeutics, Inc.	Tartrate salt of isofagomine and methods of use
BRPI0713442A2 (pt) *	2006-06-23	2012-03-06	Amicus Therapeutics, Inc.	Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase
MX2009011473A (es)	2007-04-26	2010-01-18	Amicus Therapeutics Inc	Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
US20110237538A1 (en)	2008-08-06	2011-09-29	Summit Corporation Plc	Treatment of lysosomal storage disorders and other proteostatic diseases
AU2010233188B2 (en)	2009-04-09	2015-07-16	Amicus Therapeutics, Inc.	Methods for preventing and/or treating lysosomal storage disorders
ES2505243T3 (es)	2009-04-09	2014-10-09	Amicus Therapeutics, Inc.	Agentes terapéuticos para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
ES2716871T3 (es) *	2009-10-19	2019-06-17	Amicus Therapeutics Inc	Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal
PL2490532T3 (pl) *	2009-10-19	2017-05-31	Amicus Therapeutics, Inc.	Nowe kompozycje do zapobiegania i/lub leczenia zaburzeń zwyrodnieniowych ośrodkowego układu nerwowego
ES2646099T3 (es) *	2009-10-19	2017-12-12	Amicus Therapeutics, Inc.	Método para el tratamiento de la enfermedad de Alzheimer utilizando chaperonas farmacológicas para aumentar la actividad de gangliosidasas
KR102023720B1 (ko)	2012-09-03	2019-09-20	엘지이노텍 주식회사	보이스 코일 모터

2010
- 2010-10-05 PL PL10825396T patent/PL2490532T3/pl unknown
- 2010-10-05 CN CN201510783936.0A patent/CN105367485B/zh not_active Expired - Fee Related
- 2010-10-05 KR KR1020127012936A patent/KR101769396B1/ko active IP Right Grant
- 2010-10-05 KR KR1020177037220A patent/KR101880411B1/ko active IP Right Grant
- 2010-10-05 MX MX2012004548A patent/MX340807B/es active IP Right Grant
- 2010-10-05 SI SI201031401A patent/SI2490532T1/sl unknown
- 2010-10-05 ES ES16191218T patent/ES2814178T3/es active Active
- 2010-10-05 EP EP16191218.3A patent/EP3143875B1/en active Active
- 2010-10-05 DK DK10825396.4T patent/DK2490532T3/en active
- 2010-10-05 KR KR1020177022493A patent/KR101813988B1/ko active IP Right Grant
- 2010-10-05 ES ES10825396.4T patent/ES2617192T3/es active Active
- 2010-10-05 SG SG10201507159XA patent/SG10201507159XA/en unknown
- 2010-10-05 US US12/898,112 patent/US8604206B2/en active Active
- 2010-10-05 JP JP2012535221A patent/JP5805649B2/ja active Active
- 2010-10-05 BR BR112012009121A patent/BR112012009121A2/pt not_active Application Discontinuation
- 2010-10-05 MX MX2016000153A patent/MX368459B/es unknown
- 2010-10-05 HU HUE10825396A patent/HUE033116T2/en unknown
- 2010-10-05 RU RU2012120759/04A patent/RU2581058C2/ru active
- 2010-10-05 AU AU2010308396A patent/AU2010308396B2/en not_active Ceased
- 2010-10-05 CA CA2778348A patent/CA2778348C/en active Active
- 2010-10-05 EP EP10825396.4A patent/EP2490532B1/en active Active
- 2010-10-05 PT PT108253964T patent/PT2490532T/pt unknown
- 2010-10-05 CN CN2010800566279A patent/CN102655747A/zh active Pending
- 2010-10-05 RS RS20170153A patent/RS55679B1/sr unknown
- 2010-10-05 LT LTEP10825396.4T patent/LT2490532T/lt unknown
- 2010-10-05 WO PCT/US2010/051447 patent/WO2011049736A1/en active Application Filing
- 2010-10-05 RU RU2015147509A patent/RU2015147509A/ru unknown
- 2010-10-12 AR ARP100103715A patent/AR078606A1/es unknown
- 2010-10-12 TW TW099134782A patent/TWI642434B/zh not_active IP Right Cessation
2012
- 2012-04-15 IL IL219160A patent/IL219160B/en not_active IP Right Cessation
2013
- 2013-03-01 HK HK16107625.0A patent/HK1219724A1/zh unknown
- 2013-11-19 US US14/084,131 patent/US9409862B2/en active Active
2015
- 2015-03-30 JP JP2015069784A patent/JP6258245B2/ja active Active
2016
- 2016-06-08 AU AU2016203817A patent/AU2016203817B2/en not_active Ceased
- 2016-07-22 US US15/217,217 patent/US20160326114A1/en not_active Abandoned
2017
- 2017-02-13 HR HRP20170236TT patent/HRP20170236T1/hr unknown
- 2017-02-16 SM SM201700105T patent/SMT201700105B/it unknown
- 2017-02-22 CY CY20171100240T patent/CY1118966T1/el unknown
- 2017-12-07 AU AU2017272296A patent/AU2017272296B2/en not_active Ceased
2018
- 2018-06-01 US US15/995,813 patent/US10421724B2/en active Active

Also Published As

Publication number	Publication date
ES2617192T3 (es)	2017-06-15
TW201116279A (en)	2011-05-16
CA2778348A1 (en)	2011-04-28
CN102655747A (zh)	2012-09-05
HRP20170236T1 (hr)	2017-04-07
PT2490532T (pt)	2017-02-23
RS55679B1 (sr)	2017-07-31
KR101880411B1 (ko)	2018-07-19
EP2490532B1 (en)	2016-11-23
HK1219724A1 (zh)	2017-04-13
SG10201507159XA (en)	2015-10-29
CY1118966T1 (el)	2018-01-10
PL2490532T3 (pl)	2017-05-31
MX368459B (es)	2019-10-03
HUE033116T2 (en)	2017-11-28
EP2490532A1 (en)	2012-08-29
EP2490532A4 (en)	2013-06-12
IL219160B (en)	2018-12-31
US20110092541A1 (en)	2011-04-21
EP3143875B1 (en)	2020-05-27
RU2015147509A (ru)	2019-01-14
US8604206B2 (en)	2013-12-10
BR112012009121A2 (pt)	2017-08-29
SMT201700105B (it)	2017-03-08
AU2017272296B2 (en)	2019-07-11
TWI642434B (zh)	2018-12-01
US9409862B2 (en)	2016-08-09
IL219160A0 (en)	2012-06-28
AU2016203817A1 (en)	2016-06-30
KR20120104549A (ko)	2012-09-21
JP5805649B2 (ja)	2015-11-04
ES2814178T3 (es)	2021-03-26
DK2490532T3 (en)	2017-02-27
JP2013508366A (ja)	2013-03-07
AU2017272296A1 (en)	2018-01-25
JP6258245B2 (ja)	2018-01-10
AU2016203817B2 (en)	2017-09-07
KR20170096220A (ko)	2017-08-23
RU2581058C2 (ru)	2016-04-10
KR101813988B1 (ko)	2018-01-02
SI2490532T1 (sl)	2017-03-31
MX340807B (es)	2016-07-27
KR20180001588A (ko)	2018-01-04
WO2011049736A1 (en)	2011-04-28
CN105367485B (zh)	2018-04-17
JP2015157822A (ja)	2015-09-03
AR078606A1 (es)	2011-11-23
RU2012120759A (ru)	2013-11-27
AU2010308396A1 (en)	2012-05-03
US20180273474A1 (en)	2018-09-27
AU2010308396B2 (en)	2016-04-28
EP3143875A1 (en)	2017-03-22
MX2012004548A (es)	2012-07-04
US10421724B2 (en)	2019-09-24
CN105367485A (zh)	2016-03-02
US20160326114A1 (en)	2016-11-10
US20140080871A1 (en)	2014-03-20
CA2778348C (en)	2022-08-23
KR101769396B1 (ko)	2017-08-18

Publication	Publication Date	Title
HRP20170236T1 (hr)	2017-04-07	Novi pripravci za sprječavanje i/ili liječenje degenerativnih poremećaja središnjeg živčanog sustava
HK1168005A1 (en)	2012-12-21	Methods for preventing and or treating degenerative disorders of the central nervous system
GB201001047D0 (en)	2010-03-10	Methods and compositions for the treatment of neurological disorders
IL241791A0 (en)	2015-11-30	Historical use of 3,1-diphenylprop-2-en-1-one for the treatment of liver disorders
EP2170309A4 (en)	2010-11-03	METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
EP2552433A4 (en)	2013-11-06	COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
EP2331088A4 (en)	2011-10-12	COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
IL209032A0 (en)	2011-01-31	Compositions and methods for treating digestive disorders
EP2429530A4 (en)	2012-10-31	METHOD AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC ILLNESSES
EP2550361A4 (en)	2014-04-30	COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDER
GB2495885B (en)	2017-11-22	Combination pharmaceutical composition and methods of treating genitourinary system disorders
EP2475390A4 (en)	2014-01-01	METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS
HK1205503A1 (en)	2015-12-18	Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system //
HU0900231D0 (en)	2009-06-29	Compositions for the treatment of allergic disorders
EP2219650A4 (en)	2011-04-20	COMPOSITIONS AND METHODS FOR TREATING FIBROPROLIFERATIVE DISORDERS
EP2612668A4 (en)	2014-03-19	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE NEUROLOGICAL CEREBRAL DISORDERS
EP2582832A4 (en)	2013-10-30	METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CENTRAL ANIMAL NERVOUS SYSTEM FOR PSYCHIATRIC DISORDERS
MX2011013073A (es)	2012-02-28	Compuestos 1-(2-alquil-2,3-dihidro-benzofuran-4-il)-pirrolidin-3-i laminoacilo.
EP2370087A4 (en)	2013-08-28	METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID RETENTION DISORDERS
EP2578206A4 (en)	2013-11-27	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISORDERS OF THE LOWER PART OF THE UROGENITAL SYSTEM
EP2255189A4 (en)	2012-05-02	COMPOSITIONS AND METHODS MODULATING THE G-PROTEIN SIGNALING FOR THE TREATMENT OF ASTHMA
GB0724947D0 (en)	2008-01-30	Composition for the treatment of psychiatric disorders
AU2007903760A0 (en)	2007-07-26	Composition and method for the treatment or prevention of spinal disorders